Cosmos Health Inc. (COSM)
USD 0.34
(-2.95%)
USD 0.34
(-2.95%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 30.25 Million USD | 6.59% |
| 2022 | 28.38 Million USD | -37.0% |
| 2021 | 45.04 Million USD | -6.16% |
| 2020 | 48 Million USD | 58.22% |
| 2019 | 30.34 Million USD | 26.35% |
| 2018 | 24.01 Million USD | 75.23% |
| 2017 | 13.7 Million USD | 181.31% |
| 2016 | 4.87 Million USD | 155.66% |
| 2015 | 1.9 Million USD | 8.2% |
| 2014 | 1.76 Million USD | 91.25% |
| 2013 | 920.73 Thousand USD | 65526.09% |
| 2012 | 1403.00 USD | -92.99% |
| 2011 | 20 Thousand USD | 11.41% |
| 2010 | 17.95 Thousand USD | 290.24% |
| 2009 | 4600.00 USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 27.79 Million USD | -8.11% |
| 2024 Q2 | 28.7 Million USD | 3.27% |
| 2023 FY | 30.25 Million USD | 6.59% |
| 2023 Q1 | 23.63 Million USD | -16.72% |
| 2023 Q4 | 30.25 Million USD | 12.22% |
| 2023 Q2 | 24.55 Million USD | 3.87% |
| 2023 Q3 | 26.95 Million USD | 9.8% |
| 2022 Q3 | 40.46 Million USD | 1.96% |
| 2022 FY | 28.38 Million USD | -37.0% |
| 2022 Q1 | 44.62 Million USD | -0.95% |
| 2022 Q2 | 39.68 Million USD | -11.06% |
| 2022 Q4 | 28.38 Million USD | -29.86% |
| 2021 Q1 | 44.49 Million USD | -7.3% |
| 2021 FY | 45.04 Million USD | -6.16% |
| 2021 Q2 | 44.77 Million USD | 0.61% |
| 2021 Q3 | 43.02 Million USD | -3.9% |
| 2021 Q4 | 45.04 Million USD | 4.7% |
| 2020 Q1 | 30.56 Million USD | 0.72% |
| 2020 FY | 48 Million USD | 58.22% |
| 2020 Q2 | 39.38 Million USD | 28.87% |
| 2020 Q3 | 43.33 Million USD | 10.05% |
| 2020 Q4 | 48 Million USD | 10.77% |
| 2019 Q4 | 30.34 Million USD | 9.67% |
| 2019 FY | 30.34 Million USD | 26.35% |
| 2019 Q1 | 25.25 Million USD | 5.16% |
| 2019 Q2 | 26.61 Million USD | 5.4% |
| 2019 Q3 | 27.66 Million USD | 3.95% |
| 2018 Q1 | 17.82 Million USD | 30.08% |
| 2018 Q4 | 24.01 Million USD | 47.94% |
| 2018 Q3 | 16.23 Million USD | -4.6% |
| 2018 Q2 | 17.01 Million USD | -4.56% |
| 2018 FY | 24.01 Million USD | 75.23% |
| 2017 FY | 13.7 Million USD | 181.31% |
| 2017 Q4 | 13.7 Million USD | 0.74% |
| 2017 Q3 | 13.6 Million USD | 37.67% |
| 2017 Q2 | 9.88 Million USD | 49.11% |
| 2017 Q1 | 6.62 Million USD | 36.02% |
| 2016 Q4 | 4.87 Million USD | 32.75% |
| 2016 FY | 4.87 Million USD | 155.66% |
| 2016 Q3 | 3.66 Million USD | 56.65% |
| 2016 Q2 | 2.34 Million USD | -3.07% |
| 2016 Q1 | 2.41 Million USD | 26.83% |
| 2015 Q1 | 1.55 Million USD | -11.41% |
| 2015 FY | 1.9 Million USD | 8.2% |
| 2015 Q4 | 1.9 Million USD | 11.19% |
| 2015 Q3 | 1.71 Million USD | 6.27% |
| 2015 Q2 | 1.61 Million USD | 3.37% |
| 2014 FY | 1.76 Million USD | 91.25% |
| 2014 Q4 | 1.76 Million USD | 15.42% |
| 2014 Q3 | 1.52 Million USD | 125.03% |
| 2014 Q2 | 677.99 Thousand USD | 41.11% |
| 2014 Q1 | 480.48 Thousand USD | -47.82% |
| 2013 Q3 | 1.4 Million USD | 291.57% |
| 2013 FY | 920.73 Thousand USD | 65526.09% |
| 2013 Q4 | 920.73 Thousand USD | -34.44% |
| 2013 Q1 | 300.7 Thousand USD | -11.29% |
| 2013 Q2 | 358.66 Thousand USD | 19.28% |
| 2012 Q3 | 270.02 Thousand USD | 26.68% |
| 2012 Q4 | 338.98 Thousand USD | 25.54% |
| 2012 FY | 1403.00 USD | -92.99% |
| 2012 Q1 | 161.67 Thousand USD | 37.73% |
| 2012 Q2 | 213.16 Thousand USD | 31.85% |
| 2011 Q4 | 117.38 Thousand USD | 77.56% |
| 2011 Q1 | 5000.00 USD | -68.67% |
| 2011 Q2 | 20 Thousand USD | 300.0% |
| 2011 Q3 | 66.1 Thousand USD | 230.54% |
| 2011 FY | 20 Thousand USD | 11.41% |
| 2010 Q3 | 17.02 Thousand USD | -5.14% |
| 2010 Q2 | 17.95 Thousand USD | -2.29% |
| 2010 Q1 | 18.37 Thousand USD | 8.89% |
| 2010 Q4 | 15.95 Thousand USD | -6.29% |
| 2010 FY | 17.95 Thousand USD | 290.24% |
| 2009 FY | 4600.00 USD | 0.0% |
| 2009 Q4 | 16.87 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bright Green Corporation | 6.43 Million USD | -369.898% |
| Alpha Teknova, Inc. | 38.55 Million USD | 21.526% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 93.586% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 81.543% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 96.808% |
| Journey Medical Corporation | 56.49 Million USD | 46.455% |
| Embecta Corp. | 2.03 Billion USD | 98.514% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 95.422% |
| Dynavax Technologies Corporation | 375.02 Million USD | 91.933% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 77.897% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 95.704% |
| PainReform Ltd. | 2.69 Million USD | -1024.211% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -392.744% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -392.744% |
| SCYNEXIS, Inc. | 55.45 Million USD | 45.442% |
| Safety Shot Inc | 3.89 Million USD | -677.291% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -228.953% |
| Procaps Group, S.A. | 462.06 Million USD | 93.453% |
| Theratechnologies Inc. | 98.63 Million USD | 69.33% |
| Harrow Health, Inc. | 241.75 Million USD | 87.486% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -245.506% |
| Biofrontera Inc. | 23.13 Million USD | -30.743% |
| DURECT Corporation | 30.4 Million USD | 0.505% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 93.794% |
| Cronos Group Inc. | 43.73 Million USD | 30.829% |
| OptiNose, Inc. | 194.33 Million USD | 84.433% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 96.299% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 37.553% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -44.21% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 83.319% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -702.0% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 42.394% |
| Radius Health, Inc. | 804.29 Million USD | 96.239% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -119.949% |
| ProPhase Labs, Inc. | 42.54 Million USD | 28.891% |
| Phibro Animal Health Corporation | 725.54 Million USD | 95.83% |
| Procaps Group S.A. | 462.06 Million USD | 93.453% |
| Alvotech | 1.88 Billion USD | 98.393% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -115.75% |
| Viatris Inc. | 27.21 Billion USD | 99.889% |
| Rockwell Medical, Inc. | 30.88 Million USD | 2.038% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 66.527% |
| SIGA Technologies, Inc. | 57.97 Million USD | 47.82% |
| Tilray Brands, Inc. | 892.11 Million USD | 96.609% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 86.236% |
| Shineco, Inc. | 47.6 Million USD | 36.447% |
| PetIQ, Inc. | 645.22 Million USD | 95.311% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -13681.718% |
| Incannex Healthcare Limited | 5.83 Million USD | -418.911% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 97.032% |
| Alimera Sciences, Inc. | 107.35 Million USD | 71.82% |
| Silver Spike Investment Corp. | 3 Million USD | -905.124% |
| Assertio Holdings, Inc. | 148.41 Million USD | 79.616% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -1495.627% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -41.926% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -330.58% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -256.309% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 82.552% |
| Hempacco Co., Inc. | 18.82 Million USD | -60.726% |
| Talphera, Inc. | 6.29 Million USD | -380.962% |
| Alvotech | 1.88 Billion USD | 98.393% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 82.472% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 96.378% |
| Currenc Group, Inc. | 177.67 Million USD | 82.973% |
| Kamada Ltd. | 109.96 Million USD | 72.49% |
| Indivior PLC | 1.95 Billion USD | 98.45% |
| Evoke Pharma, Inc. | 9.64 Million USD | -213.56% |
| Flora Growth Corp. | 17.22 Million USD | -75.662% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -256.309% |
| Evolus, Inc. | 209.68 Million USD | 85.573% |
| HUTCHMED (China) Limited | 536.38 Million USD | 94.36% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 96.537% |
| Akanda Corp. | 12.66 Million USD | -138.794% |